Malte Greune
Chief Operating Officer at CUREVAC N.V.
Net worth: 6 299 $ as of 2024-03-30
Profile
Malte Greune occupies the position of Chief Operating & Production Officer at CureVac NV. In the past he held the position of VP-Cartridges, Devices & Insulin Technology Group at Sanofi-Aventis Deutschland GmbH. He received a doctorate from Universität zu Köln, an undergraduate degree from the University of Trier and an MBA from Clark University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CUREVAC N.V.
0.00% | 2023-03-30 | 2,079 ( 0.00% ) | 6 299 $ | 2024-03-30 |
Malte Greune active positions
| Companies | Position | Start |
|---|---|---|
| CUREVAC N.V. | Chief Operating Officer | 2021-06-30 |
Former positions of Malte Greune
| Companies | Position | End |
|---|---|---|
Sanofi-Aventis Deutschland GmbH
 Sanofi-Aventis Deutschland GmbH Pharmaceuticals: MajorHealth Technology Sanofi-Aventis Deutschland GmbH engages in the development, manufacture, and packaging of medicines, as well as pharmaceutical products. It also focuses on the research into the causes of diseases and the search for its drug treatment. The company was founded in 2004 and is headquartered in Frankfurt, Germany. | Corporate Officer/Principal | - |
Training of Malte Greune
| Clark University | Masters Business Admin |
| Universität zu Köln | Doctorate Degree |
| University of Trier | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CUREVAC N.V. | Health Technology |
| Private companies | 1 |
|---|---|
Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis Deutschland GmbH Pharmaceuticals: MajorHealth Technology Sanofi-Aventis Deutschland GmbH engages in the development, manufacture, and packaging of medicines, as well as pharmaceutical products. It also focuses on the research into the causes of diseases and the search for its drug treatment. The company was founded in 2004 and is headquartered in Frankfurt, Germany. | Health Technology |
- Stock Market
- Insiders
- Malte Greune